Preliminary results of an open-label observational study evaluating the efficacy and safety of Prolia used in women with postmenopausal osteoporosis
AIM. To evaluate the efficacy and safety of Denosumab (Prolia), a first-line osteoporosis (OP) medication that is a fully human monoclonal antibody to the receptor activator of nuclear factor κВ ligand (RANKL), within an open-label observational study. MATERIALS AND METHODS. Patients aged 50 years o...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
"Consilium Medicum" Publishing house
2014-10-01
|
| Series: | Терапевтический архив |
| Subjects: | |
| Online Access: | https://ter-arkhiv.ru/0040-3660/article/view/31587 |
| _version_ | 1818400651895373824 |
|---|---|
| author | O B Ershova O M Lesniak K Iu Belova A V Nazarova A V Manovitskaia T M Musaeva R M Mustaev R Z Nurlygaianov L Ia Rozhinskaia I A Skripnikova N V Toroptsova |
| author_facet | O B Ershova O M Lesniak K Iu Belova A V Nazarova A V Manovitskaia T M Musaeva R M Mustaev R Z Nurlygaianov L Ia Rozhinskaia I A Skripnikova N V Toroptsova |
| author_sort | O B Ershova |
| collection | DOAJ |
| description | AIM. To evaluate the efficacy and safety of Denosumab (Prolia), a first-line osteoporosis (OP) medication that is a fully human monoclonal antibody to the receptor activator of nuclear factor κВ ligand (RANKL), within an open-label observational study. MATERIALS AND METHODS. Patients aged 50 years or older with postmenopausal OP, who were treated with Prolia in clinical practice, were examined. The concentrations of the bone resorption (BR) marker of C-terminal telopeptide and other laboratory indicators (total serum calcium, total alkaline phosphatase, and creatinine) were measured following 3 months. Adverse drug reactions were recorded. RESULTS. Three months after initiation of the investigation, there was a significant decrease in the BR marker C-terminal telopeptide (by 89%; p |
| first_indexed | 2024-12-14T07:39:58Z |
| format | Article |
| id | doaj.art-e9a4b769d62742e68657e87cd8be01e8 |
| institution | Directory Open Access Journal |
| issn | 0040-3660 2309-5342 |
| language | Russian |
| last_indexed | 2024-12-14T07:39:58Z |
| publishDate | 2014-10-01 |
| publisher | "Consilium Medicum" Publishing house |
| record_format | Article |
| series | Терапевтический архив |
| spelling | doaj.art-e9a4b769d62742e68657e87cd8be01e82022-12-21T23:11:05Zrus"Consilium Medicum" Publishing houseТерапевтический архив0040-36602309-53422014-10-018610606428603Preliminary results of an open-label observational study evaluating the efficacy and safety of Prolia used in women with postmenopausal osteoporosisO B ErshovaO M LesniakK Iu BelovaA V NazarovaA V ManovitskaiaT M MusaevaR M MustaevR Z NurlygaianovL Ia RozhinskaiaI A SkripnikovaN V ToroptsovaAIM. To evaluate the efficacy and safety of Denosumab (Prolia), a first-line osteoporosis (OP) medication that is a fully human monoclonal antibody to the receptor activator of nuclear factor κВ ligand (RANKL), within an open-label observational study. MATERIALS AND METHODS. Patients aged 50 years or older with postmenopausal OP, who were treated with Prolia in clinical practice, were examined. The concentrations of the bone resorption (BR) marker of C-terminal telopeptide and other laboratory indicators (total serum calcium, total alkaline phosphatase, and creatinine) were measured following 3 months. Adverse drug reactions were recorded. RESULTS. Three months after initiation of the investigation, there was a significant decrease in the BR marker C-terminal telopeptide (by 89%; phttps://ter-arkhiv.ru/0040-3660/article/view/31587osteoporosisc-terminal telopeptideproliadenosumab |
| spellingShingle | O B Ershova O M Lesniak K Iu Belova A V Nazarova A V Manovitskaia T M Musaeva R M Mustaev R Z Nurlygaianov L Ia Rozhinskaia I A Skripnikova N V Toroptsova Preliminary results of an open-label observational study evaluating the efficacy and safety of Prolia used in women with postmenopausal osteoporosis Терапевтический архив osteoporosis c-terminal telopeptide prolia denosumab |
| title | Preliminary results of an open-label observational study evaluating the efficacy and safety of Prolia used in women with postmenopausal osteoporosis |
| title_full | Preliminary results of an open-label observational study evaluating the efficacy and safety of Prolia used in women with postmenopausal osteoporosis |
| title_fullStr | Preliminary results of an open-label observational study evaluating the efficacy and safety of Prolia used in women with postmenopausal osteoporosis |
| title_full_unstemmed | Preliminary results of an open-label observational study evaluating the efficacy and safety of Prolia used in women with postmenopausal osteoporosis |
| title_short | Preliminary results of an open-label observational study evaluating the efficacy and safety of Prolia used in women with postmenopausal osteoporosis |
| title_sort | preliminary results of an open label observational study evaluating the efficacy and safety of prolia used in women with postmenopausal osteoporosis |
| topic | osteoporosis c-terminal telopeptide prolia denosumab |
| url | https://ter-arkhiv.ru/0040-3660/article/view/31587 |
| work_keys_str_mv | AT obershova preliminaryresultsofanopenlabelobservationalstudyevaluatingtheefficacyandsafetyofproliausedinwomenwithpostmenopausalosteoporosis AT omlesniak preliminaryresultsofanopenlabelobservationalstudyevaluatingtheefficacyandsafetyofproliausedinwomenwithpostmenopausalosteoporosis AT kiubelova preliminaryresultsofanopenlabelobservationalstudyevaluatingtheefficacyandsafetyofproliausedinwomenwithpostmenopausalosteoporosis AT avnazarova preliminaryresultsofanopenlabelobservationalstudyevaluatingtheefficacyandsafetyofproliausedinwomenwithpostmenopausalosteoporosis AT avmanovitskaia preliminaryresultsofanopenlabelobservationalstudyevaluatingtheefficacyandsafetyofproliausedinwomenwithpostmenopausalosteoporosis AT tmmusaeva preliminaryresultsofanopenlabelobservationalstudyevaluatingtheefficacyandsafetyofproliausedinwomenwithpostmenopausalosteoporosis AT rmmustaev preliminaryresultsofanopenlabelobservationalstudyevaluatingtheefficacyandsafetyofproliausedinwomenwithpostmenopausalosteoporosis AT rznurlygaianov preliminaryresultsofanopenlabelobservationalstudyevaluatingtheefficacyandsafetyofproliausedinwomenwithpostmenopausalosteoporosis AT liarozhinskaia preliminaryresultsofanopenlabelobservationalstudyevaluatingtheefficacyandsafetyofproliausedinwomenwithpostmenopausalosteoporosis AT iaskripnikova preliminaryresultsofanopenlabelobservationalstudyevaluatingtheefficacyandsafetyofproliausedinwomenwithpostmenopausalosteoporosis AT nvtoroptsova preliminaryresultsofanopenlabelobservationalstudyevaluatingtheefficacyandsafetyofproliausedinwomenwithpostmenopausalosteoporosis |